swingingtech Posted - 1 day ago

$SYK $C https://wallstreetwaves.com/stryker-stock-prognosis-analyzing-wall-streets-sentiment/

MakingMeMeoutofME Posted - 1 day ago

$MDT which Wall Street firm is upgrading the stock to 100-110 target avg EPS for 2H is 1.49 per share per qtr. off 1.23 and 1.26 in 1H stock is going to be bought $ISRG $ABT $SYK $BSX no brainer for 2-3 month

MakingMeMeoutofME Posted - 1 day ago

$MDT 85.60 lets blast to 87-88.80 then 93 $ISRG $SYK $ABT 3.27 dividend EPS now 1.37-1.39 for Q3 and 1.5 + Q4 growth vs 1.26 this qtr

MakingMeMeoutofME Posted - 1 day ago

$MDT breaks 85.60 it can run to 88.80 $BSX $ABT $SYK 3.25 divi 2H growth is here 5.47 eps and 5.85-5.90 next

MakingMeMeoutofME Posted - 2 days ago

$MDT 5.80 in FY26 at 17x = 100 per share $BSX $ABT $SYK 22-33x

MakingMeMeoutofME Posted - 2 days ago

$MDT 14.50 x FY 2026 EPS 3.20 % divi $SYK $ABT $BSX all 22+ going to 100

thayford Posted - 2 days ago

Add to winner $SYK

MakingMeMeoutofME Posted - 2 days ago

$MDT EPS in AM 1.24 on 8.26B with 5.45 eps estimate for FY25(APR) and 5.85 (FY26) trades 16x and 3% dividend while $BSX $ABT $ZBH $SYK all Trade at 20-40x

IsabellaDC Posted - 2 days ago

Monday 11/18 All time leaders: $NFLX $SYK $LPX $BSX $LYV and so on.

fitchbuck Posted - 1 week ago

$MYO $SYK nearing 150b MC, nuts.. while small medtech flails. They could flick half a percent this way, not even notice it gone, close this mom & pop down.

MakingMeMeoutofME Posted - 1 week ago

$MDT I feel an upgrade or 2 before Friday $ABT $SYK $BSX medical device plays 100 target on CEO's positive comments

MakingMeMeoutofME Posted - 1 week ago

$MDT breakout of 88.88 and we see 90 $SYK $ABT $BSX

MakingMeMeoutofME Posted - 1 week ago

$MDT ready to for 100 for all the $SYK traders to take notice $ABT $BSX traders inverse head and shoulders formed

MakingMeMeoutofME Posted - 1 week ago

$MDT still calling for an upgrade pre eps 11/19 pre mkt $BSX $ABT $SYK 2H revs EPS growth being called by CEO

contangoz Posted - 1 week ago

@Shawshank256 mine is a feed i use with ties to SEC. not sure - not too worried - its a special sit stock now as investors grapple with takeout premium bake off in IF anything happens. $thc $isrg $syk $prct is how we are playing ASC/robotics space anyways

anachartanalyst Posted - 2 weeks ago

https://anachart.com/market-update/november-1st-2024/ $META $SNAP $SYK

Thun1 Posted - 10/31/24

$SYK Will this split anytime soon?

IN0V8 Posted - 10/31/24

$SYK Opportunity Barclays raises target price to $418 from $402 Citigroup raises target price to $411 from $406

briefingcom Posted - 10/30/24

$SYK: After an immediate gap higher near all-time highs following top and bottom-line beats in Q3, shares of Stryker have started to fade. The medical device maker, specializing in joint replacement, also lifted the lower bounds of its FY24 adjusted EPS and organic net sales growth forecasts. So why are shares not as lively as they were out of the gate today? SYK trades at a premium valuation with a forward sales and earnings multiple of 5.7x and 27.3x, respectively, significantly higher than one of its key rivals, Zimmer Biomet (ZBH), which trades at half these multiples, as well as Johnson & Johnson (JNJ). Given this, SYK's earnings are placed under a microscope, where minor weaknesses are magnified. https://www.briefing.com/story-stocks/archive/2024/10/30/stryker-fades-initial-gains-following-q3-results-mostly-unchanged-fy24-guidance-weighs-(syk)-?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link

IN0V8 Posted - 10/30/24

$SYK Opportunity Deutsche Bank raises target price to $380 from $345 BTIG raises target price to $394 from $383 Canaccord Genuity raises target price to $400 from $360 Jefferies raises target price to $415 from $400 JP Morgan raises target price to $420 from $375 Needham raises target price to $409 from $393 Piper Sandler raises target price to $420 from $380 RBC raises target price to $400 from $386 Stifel raises target price to $400 from $365 Truist Securities raises target price to $380 from $370 UBS raises target price to $370 from $366 Wells Fargo raises target price to $405 from $381

RelativeStrength30 Posted - 10/30/24

$XXII $SYK Follow the only FDA approved VLN cigs on the market .10 battle happening now.

Dr_Stoxx Posted - 10/30/24

$SYK and $MDT are my favorites in that space.

OpenOutcrier Posted - 10/30/24

$SYK (+1.3% pre) Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates https://finance.yahoo.com/news/stryker-syk-surpasses-q3-earnings-212010825.html

erevnon Posted - 10/30/24

Needham maintains Stryker $SYK at Buy and raises the price target from $393 to https://marketsblock.com/stock-upgrades-and-downgrades/

anachartanalyst Posted - 10/30/24

$SYK https://anachart.com/wp-content/uploads/ana_temp/1730282472_soc-img.jpg

NokaKin Posted - 10/29/24

$SYK just send it to $400 new ATH loading🫠📈🚀

CH_Expat Posted - 10/29/24

$SYK Beast stock. Would not want to work there though, they want to make Stryker your family, a problem for those who already have one. Nevertheless, products are okay and numbers speak for themselves.

med_bull Posted - 10/28/24

$PRCT buyout 120. $JNJ $SYK $MDT $BSX

ChessGM Posted - 10/28/24

$SYK Upcoming Earnings Alert for 10/29/2024 Neutral (5.7) In analyzing Stryker Corporation (SYK), the company appears to be at a critical juncture with strong segmental performance anticipated in the upcoming third-quarter earnings report. Analysts expect a solid performance driven by its flagship robotic surgery platform, Mako, and strategic acquisitions, including Vertos Medical and NICO Corporation, which enhance its offerings in interventional pain management and neurotechnology. Financially, Stryker has shown a robust year-to-date return of 18.6%, with improvements reflected in its price-to-earnings (P/E) ratio, currently around 30.4, indicative of investor confidence despite recent insider selling which may raise concerns about future performance. Furthermore, the company's earnings per share (EPS) growth is expected to be positive, maintaining a competitive edge against industry peers, especially in light of forecasts that anticipate a steady revenue growth rate of approximately 8% to 10% over the next few quarters. Comparatively, the medical technology sector is projected to grow at a compound annual growth rate (CAGR) of 7% in the same period. Although rising costs are expected to impact margins, particularly in the short term, Stryker's diversified product portfolio and innovation strategy position it favorably against competitors. Upcoming earnings reports for Stryker are set to be released on October 29, 2024, with many analysts projecting a slight increase in both revenue and earnings. Historical performance suggests that Stryker has consistently met or exceeded earnings expectations, with a consensus estimate of around $2.08 per share for Q3 2024, marking a year-over-year increase. The anticipated impact of the latest acquisitions and the continued strength in procedure volumes are likely to contribute positively to the results. Analysts are closely monitoring these developments, as they may significantly influence stock performance in the near future, especially in a market where healthcare innovations are increasingly pivotal. - Funds were net sellers of $SYK during the previous reporting quarter. - Top 5 funds with large holdings in $SYK: * FundSmith LLP $1,822MM (Market Value). CGMFundScore: 77% * Adage Capital P $111MM (Market Value). CGMFundScore: 86% * D. E. Shaw & Co $111MM (Market Value). CGMFundScore: 82% * OrbiMed Advisors LLC $92MM (Market Value). CGMFundScore: 57% * Applied Finance Capital Management LLC $30MM (Market Value). CGMFundScore: 81% - Last 10 days performance: -2% - Last 30 days performance: -2% - Last 90 days performance: 6% Follow ChessGM! Do not miss other earnings alerts from ChessGM. Not a financial advice.

Stocksrunner Posted - 10/25/24

Big Short Plays on $ECL $PLTR $SYK $MSTR $EXLS Are These Stocks Due for a Comeback? https://stocksrunner.com/posts/1300